Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by gebremeskelon Mar 03, 2023 3:45pm
227 Views
Post# 35318397

RE:RE:RE:RE:News?

RE:RE:RE:RE:News?FGPstock - you are blaming Theralase for not living up to the speculative posts of ScienceFirst, who is just another Stockhouse poster like you and me.

We've all got opinions. Why do you expect Theralase to live up to ScienceFirst's?

Theralase wrote they would submit the BTD application in December 2022, subject to the Clinical Study Sites (“CSS”) availability to complete all required assessments.

Don't you think it's possible that one or more study sites have not yet contributed their latest data, making it impossible for Theralase to submit the application?

Theralase never wrote anything about revenues in 1Q23. If a Stockhouse poster - ScienceFirst - interpreted their statements about the beginning of the "commercialization phase" this way this is not the fault of Theralase.
<< Previous
Bullboard Posts
Next >>